-DOCSTART- -X- O
Although -X- _ O
hepatitis -X- _ O
C -X- _ O
virus -X- _ O
( -X- _ O
HCV -X- _ O
) -X- _ O
affects -X- _ O
approximately -X- _ O
130–170 -X- _ O
million -X- _ O
people -X- _ O
worldwide -X- _ O
, -X- _ O
no -X- _ O
vaccines -X- _ O
are -X- _ O
available. -X- _ O
HCV -X- _ O
is -X- _ O
an -X- _ O
important -X- _ O
cause -X- _ O
of -X- _ O
chronic -X- _ O
hepatitis -X- _ O
, -X- _ O
cirrhosis -X- _ O
and -X- _ O
hepatocellular -X- _ O
carcinoma -X- _ O
, -X- _ O
leading -X- _ O
to -X- _ O
the -X- _ O
need -X- _ O
for -X- _ O
liver -X- _ O
transplantation. -X- _ O
In -X- _ O
this -X- _ O
study -X- _ O
, -X- _ O
curcumin -X- _ B-Intervention
, -X- _ O
a -X- _ O
constituent -X- _ O
used -X- _ O
in -X- _ O
traditional -X- _ O
Chinese -X- _ O
medicine -X- _ O
, -X- _ O
has -X- _ O
been -X- _ O
evaluated -X- _ O
for -X- _ O
its -X- _ O
anti-HCV -X- _ O
activity -X- _ O
and -X- _ O
mechanism -X- _ O
, -X- _ O
using -X- _ O
a -X- _ O
human -X- _ B-Patient
hepatoma -X- _ I-Patient
cell -X- _ I-Patient
line -X- _ I-Patient
containing -X- _ I-Patient
the -X- _ I-Patient
HCV -X- _ I-Patient
genotype -X- _ I-Patient
1b -X- _ I-Patient
subgenomic -X- _ I-Patient
replicon. -X- _ I-Patient
Below -X- _ B-Outcome
the -X- _ I-Outcome
concentration -X- _ I-Outcome
of -X- _ I-Outcome
20 -X- _ I-Outcome
% -X- _ I-Outcome
cytotoxicity -X- _ I-Outcome
, -X- _ I-Outcome
curcumin -X- _ I-Outcome
dose-dependently -X- _ I-Outcome
inhibited -X- _ I-Outcome
HCV -X- _ I-Outcome
replication -X- _ I-Outcome
by -X- _ I-Outcome
luciferase -X- _ I-Outcome
reporter -X- _ I-Outcome
gene -X- _ I-Outcome
assay -X- _ I-Outcome
, -X- _ I-Outcome
HCV -X- _ I-Outcome
RNA -X- _ I-Outcome
detection -X- _ I-Outcome
and -X- _ I-Outcome
HCV -X- _ I-Outcome
protein -X- _ I-Outcome
analysis. -X- _ I-Outcome
Under -X- _ I-Outcome
the -X- _ I-Outcome
same -X- _ I-Outcome
conditions -X- _ I-Outcome
, -X- _ I-Outcome
curcumin -X- _ I-Outcome
also -X- _ I-Outcome
dose-dependently -X- _ I-Outcome
induced -X- _ I-Outcome
heme -X- _ I-Outcome
oxygenase-1 -X- _ I-Outcome
with -X- _ I-Outcome
the -X- _ I-Outcome
highest -X- _ I-Outcome
induction -X- _ I-Outcome
at -X- _ I-Outcome
24 -X- _ I-Outcome
h. -X- _ I-Outcome
Hemin -X- _ I-Outcome
, -X- _ I-Outcome
a -X- _ I-Outcome
heme -X- _ I-Outcome
oxygenase-1 -X- _ I-Outcome
inducer -X- _ I-Outcome
, -X- _ I-Outcome
also -X- _ I-Outcome
inhibited -X- _ I-Outcome
HCV -X- _ I-Outcome
protein -X- _ I-Outcome
expression -X- _ I-Outcome
in -X- _ I-Outcome
a -X- _ I-Outcome
dose-dependent -X- _ I-Outcome
manner. -X- _ I-Outcome
The -X- _ I-Outcome
knockdown -X- _ I-Outcome
of -X- _ I-Outcome
heme -X- _ I-Outcome
oxygenase-1 -X- _ I-Outcome
partially -X- _ I-Outcome
reversed -X- _ I-Outcome
the -X- _ I-Outcome
curcumin-inhibited -X- _ I-Outcome
HCV -X- _ I-Outcome
protein -X- _ I-Outcome
expression. -X- _ I-Outcome
In -X- _ I-Outcome
addition -X- _ I-Outcome
to -X- _ I-Outcome
the -X- _ I-Outcome
heme -X- _ I-Outcome
oxygenase-1 -X- _ I-Outcome
induction -X- _ I-Outcome
, -X- _ I-Outcome
signaling -X- _ I-Outcome
molecule -X- _ I-Outcome
activities -X- _ I-Outcome
of -X- _ I-Outcome
AKT -X- _ I-Outcome
, -X- _ I-Outcome
extracellular -X- _ I-Outcome
signal-regulated -X- _ I-Outcome
kinases -X- _ I-Outcome
( -X- _ I-Outcome
ERK -X- _ I-Outcome
) -X- _ I-Outcome
and -X- _ I-Outcome
nuclear -X- _ I-Outcome
factor-κB -X- _ I-Outcome
( -X- _ I-Outcome
NF-κB -X- _ I-Outcome
) -X- _ I-Outcome
were -X- _ I-Outcome
inhibited -X- _ I-Outcome
by -X- _ I-Outcome
curcumin. -X- _ I-Outcome
Using -X- _ I-Outcome
specific -X- _ I-Outcome
inhibitors -X- _ I-Outcome
of -X- _ I-Outcome
PI3K-AKT -X- _ I-Outcome
, -X- _ I-Outcome
MEK-ERK -X- _ I-Outcome
and -X- _ I-Outcome
NF-κB -X- _ I-Outcome
, -X- _ I-Outcome
the -X- _ I-Outcome
results -X- _ I-Outcome
suggested -X- _ I-Outcome
that -X- _ I-Outcome
only -X- _ I-Outcome
PI3K-AKT -X- _ I-Outcome
inhibition -X- _ I-Outcome
is -X- _ I-Outcome
positively -X- _ I-Outcome
involved -X- _ I-Outcome
in -X- _ I-Outcome
curcumin- -X- _ I-Outcome
inhibited -X- _ I-Outcome
HCV -X- _ I-Outcome
replication. -X- _ I-Outcome
Inhibition -X- _ I-Outcome
of -X- _ I-Outcome
ERK -X- _ I-Outcome
and -X- _ I-Outcome
NF-κB -X- _ I-Outcome
was -X- _ I-Outcome
likely -X- _ I-Outcome
to -X- _ I-Outcome
promote -X- _ I-Outcome
HCV -X- _ I-Outcome
protein -X- _ I-Outcome
expression. -X- _ I-Outcome
In -X- _ I-Outcome
summary -X- _ I-Outcome
, -X- _ I-Outcome
curcumin -X- _ I-Outcome
inhibited -X- _ I-Outcome
HCV -X- _ I-Outcome
replication -X- _ I-Outcome
by -X- _ I-Outcome
heme -X- _ I-Outcome
oxygenase-1 -X- _ I-Outcome
induction -X- _ I-Outcome
and -X- _ I-Outcome
AKT -X- _ I-Outcome
pathway -X- _ I-Outcome
inhibition. -X- _ I-Outcome
Although -X- _ O
curcumin -X- _ B-Intervention
also -X- _ O
inhibits -X- _ O
ERK -X- _ O
and -X- _ O
NF-κB -X- _ O
activities -X- _ O
, -X- _ O
it -X- _ O
slightly -X- _ O
increased -X- _ O
the -X- _ O
HCV -X- _ O
protein -X- _ O
expression. -X- _ O
This -X- _ O
result -X- _ O
may -X- _ O
provide -X- _ O
information -X- _ O
when -X- _ O
curcumin -X- _ B-Intervention
is -X- _ O
used -X- _ O
as -X- _ O
an -X- _ O
adjuvant -X- _ O
in -X- _ O
anti-HCV -X- _ O
therapy -X- _ O
. -X- _ O

